Core Viewpoint - The article emphasizes the importance of investing in high-quality growth and momentum stocks that are reasonably priced, with a focus on long-term performance and market outperformance [1] Group 1: Investment Strategy - The investment strategy involves focusing on growth and momentum stocks that are expected to outperform the market over the long term [1] - The analyst has a history of advising investors to buy at market lows, specifically mentioning a recommendation in March 2009 during the financial crisis, which led to significant market gains [1] Group 2: Market Performance - From 2009 to 2019, the S&P 500 increased by 367% and the Nasdaq increased by 685%, highlighting the potential for substantial returns in the stock market [1]

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that ...

Core Viewpoint - Exelixis, Inc. (EXEL) is perceived to have significant growth potential that is not being adequately recognized in the market [1]. Group 1: Company Overview - Exelixis, Inc. is highlighted as a company with one of the highest growth potentials in the medium term [1]. Group 2: Analyst Background - The analyst has over six years of experience in the investment sector, with a background in equity analysis across various industries [1]. - The analyst's educational qualifications include a bachelor's degree from Antwerp, a master's from KU Leuven, and an MBA in Finance from Vlerick [1]. Group 3: Investment Focus - The analyst is currently building an investment project focused on the CIS region, applying Western analytical tools to identify hidden value in emerging markets [1].

Group 1 - Exelixis, Inc. is ranked eighth among the Top 10 Oncology Stocks to Buy Now [1] - H.C. Wainwright analyst Robert Burns raised the price target on EXEL to $52 from $49 while maintaining a Buy rating, citing zanzalintinib's commercial potential as a key value driver [2] - Morgan Stanley downgraded Exelixis, Inc. to Equal Weight from Overweight and raised its price target to $48 from $45, noting the stock's recent performance and the anticipated commercial launch of zanzalintinib in 2026 [3] Group 2 - Exelixis reported preliminary 2025 revenues of approximately $2.32 billion and forecasts sales of $2.525–$2.625 billion for 2026, which are significant for analysts' models [4] - The company focuses on developing small molecules for cancer treatment, with primary products CABOMETYX and COMETRIQ targeting multiple tyrosine kinases involved in tumor growth [4]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid capacity and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports [5][6] Financial Position - The company is noted for being debt-free and holding a substantial cash reserve, which is nearly one-third of its market capitalization, providing a strong financial foundation [8] - It is trading at less than 7 times earnings, indicating a potentially undervalued investment opportunity compared to its peers in the energy and utility sectors [10] Market Trends - The company is strategically aligned with several market trends, including the onshoring boom driven by tariffs, a surge in U.S. LNG exports, and a unique position in nuclear energy [14][7] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of investing in AI-related infrastructure [12] Future Outlook - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19] - The company is positioned to capitalize on the disruption caused by AI, which is reshaping traditional industries and creating new investment opportunities [11][12]

Group 1 - Exelixis is the final presenting company at the 44th Annual JPMorgan Healthcare Conference [1] - The presentation will be led by President and CEO Michael Morrissey [1][2]

Summary of Exelixis Conference Call Company Overview - **Company**: Exelixis - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Presenter**: Michael Morrissey, President and CEO Key Industry Insights - **Focus on Oncology**: Exelixis is dedicated to improving cancer treatment through innovative therapies, particularly in solid tumors, leveraging their expertise in biology, pharmacology, and clinical sciences [4][5][6] - **Franchise Building**: The company emphasizes building multiple blockbuster franchises rather than focusing on single indications, aiming to maximize value for patients and shareholders [4][6][30] Financial Performance - **2025 Preliminary Results**: - Total revenues: $2.32 billion - Net product revenues: $2.123 billion - R&D expenses: approximately $825 million - Cash at year-end: $1.65 billion [13][14] - **2026 Guidance**: - Net product revenue expected between $2.325 billion and $2.425 billion, with a midpoint of $2.375 billion - R&D expenses projected between $875 million and $925 million [14][15] Product Pipeline and Growth Strategy - **Cabozantinib (Cabo)**: - Continues to be the primary revenue driver, maintaining its position as the top TKI in the U.S. for renal cell carcinoma (RCC) [7][13] - Cumulative growth of 30% from 2023 to 2025 [13] - **Zanzalitinib (Zanza)**: - Aiming to establish Zanza as a significant oncology franchise, with ongoing pivotal trials in RCC, colorectal cancer (CRC), and neuroendocrine tumors (NET) [9][10][29] - First regulatory filing for CRC submitted in Q4 2025 [9][15] - **Pipeline Expansion**: - Four molecules currently in clinical trials, with plans for additional investigational new drug (IND) applications [10][12] Market Opportunities - **Colorectal Cancer (CRC)**: - Identified as a fragmented market with a $1.5 billion opportunity, with strategies to position Zanza effectively against competitors [32][33] - **Neuroendocrine Tumors (NET)**: - Projected market growth from $2.5 billion to over $7 billion, with a focus on innovative therapies [29] Strategic Approach - **Combination Therapies**: - Emphasis on developing combination therapies that leverage different mechanisms of action to enhance treatment efficacy [24][25][26] - **Market Leadership**: - Aiming to establish leadership in multiple tumor types, including RCC and CRC, while focusing on improving patient outcomes and standard of care [17][22] Shareholder Returns - **Capital Allocation**: - $2.16 billion returned to shareholders through share repurchase programs since March 2023, with an ongoing $750 million program [12][30] Conclusion - Exelixis is strategically positioned to leverage its strong product pipeline and market insights to drive growth in the oncology sector, focusing on building franchises that enhance patient care and deliver shareholder value. The company is committed to disciplined capital allocation and innovative research to maintain its competitive edge in the market [30][38]

J.P. MORGAN 2026 HEALTHCARE CONFERENCE JANUARY 12, 2026 Building Next-Generation Oncology Franchises Michael M. Morrissey, Ph.D. President and CEO Safe Harbor Statement This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, statements related to: Exelixis' strategy to build franchises in key solid tumors; Exelixis' goal to become a leader in oncology R&D and a top 5 solid tumor oncology company, with multiple blockbuster produc ...

Financial Performance - Exelixis reported preliminary U.S. net product revenues of approximately $2.123 billion for fiscal year 2025[1]. - The company provided fiscal year 2026 net product revenues guidance of $2.325 billion to $2.425 billion[2]. - Total revenues for fiscal year 2025 are estimated at around $2.320 billion, with guidance for 2026 set at $2.525 billion to $2.625 billion[4]. - The effective tax rate for fiscal year 2026 is projected to be between 21% and 23%[4]. - Exelixis' preliminary financial results for FY 2025 are being finalized, with the company cautioning that these results are based on preliminary information and may differ from audited results[22]. Research and Development - Research and development expenses for fiscal year 2025 are approximately $825 million, with guidance for 2026 ranging from $875 million to $925 million[4]. - Exelixis anticipates continued growth in the cabozantinib franchise, which is the leading tyrosine kinase inhibitor in renal cell carcinoma and neuroendocrine tumors[8]. - The company expects to initiate the STELLAR-316 trial in mid-2026, evaluating zanzalintinib in patients with resected stage II/III colorectal cancer[14]. - Exelixis plans to advance two programs into clinical development in 2026, including LITESPARK-033 and STELLAR-201[14]. - The company is progressing XL309, XB010, XB628, and XB371 into full development as part of its strategy to build next-generation oncology franchises[21]. - The company is focused on advancing its pipeline, including the clinical development of XL557 and XB773, contingent on supportive phase 1 data[21]. Commercial Strategy - Exelixis anticipates 2026 to be a significant year for clinical, regulatory, and commercial progress, focusing on expanding its cabozantinib business and developing zanzalintinib[20]. - The company aims to establish lasting franchises in renal cell carcinoma (RCC), neuroendocrine tumors (NET), and colorectal cancer (CRC), while driving sustained growth and returning capital to shareholders[20]. - Exelixis expects continued strong commercial performance of cabozantinib, with anticipated growth in RCC and NET in 2026, including plans to expand its gastrointestinal (GI) sales team[20]. - The regulatory review process for zanzalintinib's NDA for previously metastatic CRC in combination with atezolizumab is underway, with potential first commercial launch planned[20]. - Exelixis plans to initiate several pivotal trials, including STELLAR-316 and STELLAR-301, in 2026, and expects clinical data readouts from STELLAR-303 and STELLAR-304[20]. - The company emphasizes the importance of maintaining adequate sales, marketing, and distribution capabilities for its products to ensure market acceptance[21]. Shareholder Returns - Exelixis has repurchased a total of $2.16 billion of its common stock since March 2023, retiring 76.7 million shares[16].

Key Takeaways EXEL reported preliminary 2025 revenues of approximately $2.32B and issued 2026 guidance of $2.525 -$2.625B.EXEL's Cabometyx led RCC and expanded into pNET and epNET in 2025, supporting sales growth into 2026.EXEL filed an NDA for zanzalintinib in metastatic CRC and is preparing for its first potential launch.Exelixis, Inc. (EXEL) reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for fiscal 2026, and provided a business update.However, the stock ...